Yukiko Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yukiko Kimura has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Gary A. Walco
2 shared publications- América G Uribe
British Columbia Children's Hospital, Vancouver, BC, Canada
1 shared publication Andreas Reiff
1 shared publicationDonna Hummell
1 shared publicationEtan Sugarman
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey
1 shared publicationGary A Walco
Boston Children s Hospital
1 shared publication
Latest Publications
- Open Access
- 13 January 2010
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 8 (1) , 3
Anesthesia for intra-articular corticosteroid injections in juvenile idiopathic arthritis: A survey of pediatric rheumatologists
To determine the methods of anesthesia currently being used by pediatric rheumatologists when performing intra-articular corticosteroid injections (IACI). A questionnaire was emailed to all members of the Childhood Arthritis & Rheumatology Research Alliance, a pediatric rheumatology research network in North America. The questionnaire consisted of 11 questions ranging from procedure technique, treatments prescribed for topical anesthesia and oral analgesia, and factors that might affect procedural pain. Seventy-four of 161 physicians (46%) responded to the questionnaire. On average, each physician injected 33 children (median 25, range 1-160) and 43 joints (median 30, range 1-150) yearly. Local anesthesia was used in children on average >/= 8 years (range 2-16 years), with general anesthesia being more frequently used for younger children. All respondents used local anesthesia. The most commonly used methods of local anesthesia were EMLA((R) )cream plus subcutaneous lidocaine (58.8%), ethyl chloride spray only (39.7%), EMLA((R) )cream only (33.8%), subcutaneous lidocaine only (25%), and lidocaine iontophoresis only (11.8%). Buffering of the lidocaine was routinely done only 7.4% of the time. Although pediatric rheumatologists in North America perform IACI on a large number of patients each year, a wide variety of methods are used to deliver local anesthesia with no accepted standard of care. More studies are needed to determine the optimal method of local anesthesia delivery to minimize pain associated with IACI.
- 13 January 2010
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 8 (1) , 3
Open AccessAnesthesia for intra-articular corticosteroid injections in juvenile idiopathic arthritis: A survey of pediatric rheumatologists
To determine the methods of anesthesia currently being used by pediatric rheumatologists when performing intra-articular corticosteroid injections (IACI). A questionnaire was emailed to all members of the Childhood Arthritis & Rheumatology Research Alliance, a pediatric rheumatology research network in North America. The questionnaire consisted of 11 questions ranging from procedure technique, treatments prescribed for topical anesthesia and oral analgesia, and factors that might affect procedural pain. Seventy-four of 161 physicians (46%) responded to the questionnaire. On average, each physician injected 33 children (median 25, range 1-160) and 43 joints (median 30, range 1-150) yearly. Local anesthesia was used in children on average >/= 8 years (range 2-16 years), with general anesthesia being more frequently used for younger children. All respondents used local anesthesia. The most commonly used methods of local anesthesia were EMLA((R) )cream plus subcutaneous lidocaine (58.8%), ethyl chloride spray only (39.7%), EMLA((R) )cream only (33.8%), subcutaneous lidocaine only (25%), and lidocaine iontophoresis only (11.8%). Buffering of the lidocaine was routinely done only 7.4% of the time. Although pediatric rheumatologists in North America perform IACI on a large number of patients each year, a wide variety of methods are used to deliver local anesthesia with no accepted standard of care. More studies are needed to determine the optimal method of local anesthesia delivery to minimize pain associated with IACI.
- 1 April 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (4) , 210-218
Treatment of chronic pain in pediatric rheumatic disease
Ature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 1 April 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (4) , 210-218
Treatment of chronic pain in pediatric rheumatic disease
Ature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 1 November 2006
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 8 (6) , 480-488
Pain in children with rheumatic diseases
Pain is common in rheumatic diseases in children. Despite recent advances in arthritis treatment, pain continues to be a problem impacting daily functioning and quality of life, and no standard of care for pain management exists. The pathogenesis of pain in children with rheumatic diseases is multifactorial, and treatment of the disease alone may not be enough. Current pain treatment often includes acetaminophen, nonsteroidal anti-inflammatory drugs, and medications that treat arthritis such as methotrexate and etanercept. Nonpharmacologic interventions, such as exercise and cognitive-behavioral therapy as well as the use of analgesics such as opioids in patients whose pain is refractory to standard therapies, should also be considered. The use of systemic corticosteroids to treat pain in children with arthritis should be avoided. Idiopathic pain may coexist in children with rheumatic disease, but treatment of idiopathic pain is different than that of pain due to inflammatory disorders.
- 1 November 2006
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 8 (6) , 480-488
Pain in children with rheumatic diseases
Pain is common in rheumatic diseases in children. Despite recent advances in arthritis treatment, pain continues to be a problem impacting daily functioning and quality of life, and no standard of care for pain management exists. The pathogenesis of pain in children with rheumatic diseases is multifactorial, and treatment of the disease alone may not be enough. Current pain treatment often includes acetaminophen, nonsteroidal anti-inflammatory drugs, and medications that treat arthritis such as methotrexate and etanercept. Nonpharmacologic interventions, such as exercise and cognitive-behavioral therapy as well as the use of analgesics such as opioids in patients whose pain is refractory to standard therapies, should also be considered. The use of systemic corticosteroids to treat pain in children with arthritis should be avoided. Idiopathic pain may coexist in children with rheumatic disease, but treatment of idiopathic pain is different than that of pain due to inflammatory disorders.
- Open Access
- 6 February 2006
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (1) , 81-85
Treatment of pain in juvenile idiopathic arthritis: A survey of pediatric rheumatologists
Objective: To assess the opinions and current practice of pediatric rheumatologists regarding treatment of chronic pain in children with juvenile idiopathic arthritis (JIA).Methods: Standardized questionnaires were distributed to pediatric rheumatologists who are members of the Children's Arthritis and Rheumatology Research Alliance. Demographic data, opinions, and attitudes were solicited about pain assessment, current treatment of JIA with residual pain, and actual use of opioids to treat pain in children with JIA.Results: Of 99 rheumatologists who were contacted, 53 responses were received (53.5%). No significant demographic differences were found in attitudes about pain management and use of opioids. A total of 77.3% of respondents agreed that there are patients who continue to have significant pain despite adequate treatment. However, 59.6% disagreed with the use of opioid analgesics for treatment of those patients. Cross tabulations showed significant relationships between attitudes about opioid use and concerns for side effects, including drowsiness, fatigue, and constipation (χ2 = 1.16, P > 0.05), as well as addiction (χ2 = 5.51, P = 0.019). Thirty percent of those who strongly disagreed with opioid use and 52.4% of those who disagreed had in fact prescribed opioids in the past year. The most commonly prescribed opioids were codeine and oxycodone. Practitioners' perceived knowledge of the drugs significantly affected their likelihood to prescribe them.Conclusion: Pediatric rheumatologists are divided in their attitudes regarding treatment of residual pain in children with JIA. Concern for side effects appears to be a major factor in the decision to prescribe these analgesics. More data are needed to facilitate clearer cost‐benefit analyses in the decision to prescribe opioids to this clinical population.
- 6 February 2006
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (1) , 81-85
Open AccessTreatment of pain in juvenile idiopathic arthritis: A survey of pediatric rheumatologists
Objective: To assess the opinions and current practice of pediatric rheumatologists regarding treatment of chronic pain in children with juvenile idiopathic arthritis (JIA).Methods: Standardized questionnaires were distributed to pediatric rheumatologists who are members of the Children's Arthritis and Rheumatology Research Alliance. Demographic data, opinions, and attitudes were solicited about pain assessment, current treatment of JIA with residual pain, and actual use of opioids to treat pain in children with JIA.Results: Of 99 rheumatologists who were contacted, 53 responses were received (53.5%). No significant demographic differences were found in attitudes about pain management and use of opioids. A total of 77.3% of respondents agreed that there are patients who continue to have significant pain despite adequate treatment. However, 59.6% disagreed with the use of opioid analgesics for treatment of those patients. Cross tabulations showed significant relationships between attitudes about opioid use and concerns for side effects, including drowsiness, fatigue, and constipation (χ2 = 1.16, P > 0.05), as well as addiction (χ2 = 5.51, P = 0.019). Thirty percent of those who strongly disagreed with opioid use and 52.4% of those who disagreed had in fact prescribed opioids in the past year. The most commonly prescribed opioids were codeine and oxycodone. Practitioners' perceived knowledge of the drugs significantly affected their likelihood to prescribe them.Conclusion: Pediatric rheumatologists are divided in their attitudes regarding treatment of residual pain in children with JIA. Concern for side effects appears to be a major factor in the decision to prescribe these analgesics. More data are needed to facilitate clearer cost‐benefit analyses in the decision to prescribe opioids to this clinical population.
- 1 May 2005
- Vol. 32 (5) , 935-42
Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
. To assess the efficacy and safety of etanercept in a large cohort of children with refractory systemic onset juvenile rheumatoid arthritis (SOJRA). Standardized questionnaires were sent to US pediatric rheumatologists about patients with SOJRA treated with etanercept. Data were collected at baseline and at the last visit on etanercept. Response to treatment was assessed and compared to baseline as the mean percentage reduction in the following: acute phase reactants, prednisone dose, active joint count, and physician global assessment of disease activity. Response was defined as poor if the mean reduction was < 30%, fair if 30% to < 50%, good if 50% to < 70%, and excellent if > 70%. We analyzed data obtained by survey of 82 SOJRA patients treated with etanercept for a mean of 25 months. Poor response to treatment was observed in 45% of the children, fair response in 9%, good in 13%, and excellent in 33%. Baseline steroid therapy could be discontinued in 27/59 (46%) patients. One or more disease flares occurred in 45% of all patients. Twenty-nine patients (35%) discontinued therapy, mostly due to lack of response or flare. There were 32 adverse event reports, most not considered serious, except for 2 cases of macrophage activation syndrome. In this cohort of children with SOJRA, 46% had a good or excellent response, and most were able to reduce concomitant corticosteroid doses. The response to etanercept was fair or poor in more than half our study population, and disease flares were common. Due to the unique cytokine profile of SOJRA, tumor necrosis factor blockade may not be the optimal therapeutic approach for children with treatment-resistant SOJRA.
- 1 May 2005
- Vol. 32 (5) , 935-42
Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
. To assess the efficacy and safety of etanercept in a large cohort of children with refractory systemic onset juvenile rheumatoid arthritis (SOJRA). Standardized questionnaires were sent to US pediatric rheumatologists about patients with SOJRA treated with etanercept. Data were collected at baseline and at the last visit on etanercept. Response to treatment was assessed and compared to baseline as the mean percentage reduction in the following: acute phase reactants, prednisone dose, active joint count, and physician global assessment of disease activity. Response was defined as poor if the mean reduction was < 30%, fair if 30% to < 50%, good if 50% to < 70%, and excellent if > 70%. We analyzed data obtained by survey of 82 SOJRA patients treated with etanercept for a mean of 25 months. Poor response to treatment was observed in 45% of the children, fair response in 9%, good in 13%, and excellent in 33%. Baseline steroid therapy could be discontinued in 27/59 (46%) patients. One or more disease flares occurred in 45% of all patients. Twenty-nine patients (35%) discontinued therapy, mostly due to lack of response or flare. There were 32 adverse event reports, most not considered serious, except for 2 cases of macrophage activation syndrome. In this cohort of children with SOJRA, 46% had a good or excellent response, and most were able to reduce concomitant corticosteroid doses. The response to etanercept was fair or poor in more than half our study population, and disease flares were common. Due to the unique cytokine profile of SOJRA, tumor necrosis factor blockade may not be the optimal therapeutic approach for children with treatment-resistant SOJRA.